AMR Conference 2020


BARDA provides US$20.7m for novel antibiotic to fight resistant infections

HHS’s Biomedical Advanced Research and Development Authority, or BARDA, will provide up to $20.7 million over 2 years to VenatoRx Pharmaceuticals as part of a cost-sharing contract to develop an antibiotic to combat drug-resistant infections, the pharmaceutical company announced.